Navigation Links
Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
Date:5/22/2008

induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. In Canada, RELISTOR (methylnaltrexone bromide injection) for subcutaneous use is indicated for the treatment of OIC in patients with advanced illness receiving palliative care. Applications are pending related to the potential marketing of RELISTOR in Europe, where a Positive Opinion has been rendered by the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, as well as in Australia and other countries. In the area of virology, Progenics is developing the HIV entry inhibitor PRO 140, a humanized monoclonal antibody targeting the entry co-receptor CCR5, which has completed phase 1b clinical studies with positive results. PRO 140 is currently in phase 2 clinical testing. Pre-clinical programs for the development of novel HCV entry inhibitors are also underway. In the area of oncology, the Company is developing a human monoclonal antibody-drug conjugate (ADC) for the treatment of prostate cancer -- a selectively targeted cytotoxic antibody directed against prostate-specific membrane antigen (PSMA). PSMA is a protein found on the surface of prostate cancer cells as well as in blood vessels supplying other solid tumors. Progenics is also developing vaccines designed to treat prostate cancer by stimulating an immune response to PSMA.

DISCLOSURE NOTICE: The information contained in this document is current as of May 9, 2008. This press release contains forward-looking statements. Any statements contained herein that are not statements of historical fact may be forward-looking statements. When the Company uses the words 'anticipates,' 'plans,' 'expects' and similar expressions, it is identifying forward-looking statements. Such forward-looking statements involve risks and uncertainties which may cause the Company's actual results, performance or achievements to
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
3. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  CVS Caremark Corporation (NYSE: CVS ) ... 5, 2014, at 8:30 a.m. (EDT) with analysts and ... An audio webcast of the conference call ... of the CVS Caremark website for all interested parties.  ... webcast will be archived and available on the web ...
(Date:7/25/2014)... MARLTON, N.J. , July 25, 2014 /PRNewswire/ ... visibility, brand protection and serialization solutions, has recently ... Business" that addresses current and future needs ... solutions for the old supply chain model no ... advances in technology, including the growth of mobile ...
(Date:7/25/2014)... July 25, 2014 Research and Markets ... Ophthalmic Diagnostic Devices Market 2014-2018" report to their ... About Ophthalmic Diagnostic Device An ... identify a defect or deficiency in the human visual ... disorders such as presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... 9, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... company,s chairman and chief executive officer, is scheduled to ... next week. Details of the events are as follows:Tuesday, ... & Investor ConferencePanel Topic:  "Rheumatoid Arthritis: the Real Joint ...
... YORK, Feb. 9, 2011 Reportlinker.com announces that ... its catalogue: Adalimumab - ... http://www.reportlinker.com/p0366162/Adalimumab---Comprehensive-patent-search.html Eliminate unnecessary risk with ... Pipeline Developer is a regularly updated, professional ...
Cached Medicine Technology:Rigel Announces Participation at Two Investor Conferences 2Reportlinker Adds Adalimumab - Comprehensive Patent Search 2Reportlinker Adds Adalimumab - Comprehensive Patent Search 3Reportlinker Adds Adalimumab - Comprehensive Patent Search 4
(Date:7/25/2014)... As reported by People Magazine in the article ... and Getting Sober (7/15), one of the most popular ... out to the public about his personal transformation. Now, two ... admits that moving on with his life was a challenge. ... drugs in 2012 and even spent some time in rehab. ...
(Date:7/25/2014)... San Diego, CA (PRWEB) July 25, 2014 ... regarding all the latest information from the FDA on ... on July 21, that one lot of Ibuprofen and one ... recalled due to mislabeled packaging. Oxcarbazepine is used ... with epilepsy. , The reason for the recall ...
(Date:7/25/2014)... 25, 2014 Parker Waichman LLP, a ... consumers comments on a recent tobacco lawsuit in which ... $23.6 billion in punitive damages. Cynthia Robinson brought the ... The case is Cynthia Robinson v. R.J. Reynolds Tobacco ... First Circuit Court, Escambia County, Florida; Case Number 2008 ...
(Date:7/25/2014)... 2014 Drexel University College of Medicine ... MS, FACP, has been appointed vice dean for education, effective ... from The Commonwealth Medical College, where she is currently chair ... affairs, and professor of medicine. , As a member ... Weber had a major role in many aspects of the ...
(Date:7/25/2014)... vulnerable neurons and reduce motor deficits in a ... University School of Medicine have shown. , The ... Parkinson,s Disease . , The findings demonstrate that ... at sufficient levels and have beneficial effects when ... Previous studies of XPro1595 in animals tested more ...
Breaking Medicine News(10 mins):Health News:'The Situation' Celebrates 8 Months of Sobriety 2Health News:'The Situation' Celebrates 8 Months of Sobriety 3Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 2Health News:A Florida Jury Awards Widow More Than $23 Billion in Punitive Damages in a Lawsuit Brought Against Tobacco Maker, R.J. Reynolds, Parker Waichman LLP Comments 3Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 2Health News:Valerie D. Weber, MD, Appointed Vice Dean for Education at Drexel University College of Medicine 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2
... PLAINS, N.Y., Oct. 11 "Every Baby Has,a Story," a ... as well as those who need help to survive and ... "This storytelling project lets proud parents all over the country ... said Dr. Jennifer L.,Howse, president of the March of Dimes. ...
... TORONTO, Oct. 10 /PRNewswire/ - CBM President Professor ... for the World Health,Organizations global initiative to eliminate ... the eve of World Sight Day 2007 at ... their longstanding 20 year partnership and,support, both financially ...
... Urges Passage of Plan to Give Access to Affordable ... one week after Cover,All Pennsylvanians, the centerpiece of his ... G. Rendell today held a,town meeting in Erie as ... tour will highlight the need to lower health care ...
... Ganz, President and Chief,Executive Officer of Regence, has been ... health policy experts convened by The Aspen Institute.,The organization ... the,national dialogue on health care reform leading up to ... Stewardship Project will expand the health care debate,to the ...
... who are given drugs in addition to lumpectomies or radiotherapy, ... drugs. This is especially true if their tumors respond to ... published in the online journal, Breast Cancer Research. , "Developing ... terms of survival," explained lead researcher Dr J van der ...
... urges Congress to,pass legislation this year to ... WASHINGTON, Oct. 10 The Health IT ... and former,Representative Nancy Johnson, today applauded Representatives ... that will bring health,information technology to all ...
Cached Medicine News:Health News:'Every Baby Has a Story' Campaign Tours the Nation for March of Dimes 2Health News:World Health Organization thanks CBM For their outstanding work 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 2Health News:Governor Rendell Launches 'Tour to Insure' In Erie; 3Health News:Regence CEO to Chair National Effort Promoting Broader Health Care Stewardship 2Health News:Regence CEO to Chair National Effort Promoting Broader Health Care Stewardship 3Health News:Cancer conflict with chemotherapy treatment 2Health News:Health IT Now! Coalition Applauds Representatives Eshoo and Rogers for Introducing Health IT Legislation 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: